Most Recent
Lexapro maker squares off with generics in latest IP battle
Intellectual Property 2018-04-16 9:19 pm By Miklos Bolza

The maker of the anti-depressant Lexapro faced off Monday against Apotex, Aspen Pharma and Sandoz at a court hearing over the rights to make generic […]

Subscribe for instant access to all Lawyerly content.

Already a subscriber?

Lost your password?

Contact us to enquire about group subscriptions.

Ethicon plaintiffs win post-trial bid to expand class
Product Liability 2018-04-16 9:14 pm By Cat Fredenburgh

The applicants in a class action against Johnson & Johnson over allegedly defective vaginal mesh products have won court approval to expand the size of […]

Subscribe for instant access to all Lawyerly content.

Already a subscriber?

Lost your password?

Contact us to enquire about group subscriptions.

Pelvic mesh report calls for medical device registry
Product Liability 2018-03-29 10:37 am By Cat Fredenburgh

A long-awaited congressional report has called for an overhaul of medical device regulation in Australia, in the wake of a system-wide failure to protect women […]

Subscribe for instant access to all Lawyerly content.

Already a subscriber?

Lost your password?

Contact us to enquire about group subscriptions.

Biogen to pull MS drug in Australia following encephalitus reports
Healthcare 2018-03-16 11:43 am By Cat Fredenburgh

Biogen said Thursday it will pull its multiple sclerosis drug Zinbryta in Australia, nearly two weeks after the biotech company issued a worldwide withdrawal of […]

Subscribe for instant access to all Lawyerly content.

Already a subscriber?

Lost your password?

Contact us to enquire about group subscriptions.

Shine sets sights on new target in pelvic mesh class action
Product Liability 2018-03-08 3:18 pm By Cat Fredenburgh

As Shine Lawyers awaits judgment in a marathon class action against Johnson & Johnson over its pelvic mesh implants, a separate class action by the […]

Subscribe for instant access to all Lawyerly content.

Already a subscriber?

Lost your password?

Contact us to enquire about group subscriptions.

GSK, Novartis concede more ground in ACCC’s Voltaren case
Competition & Consumer Protection 2018-03-06 8:07 pm By Cat Fredenburgh

GlaxoSmithKline and Novartis have made another admission in a case brought by the ACCC alleging the drug giants made misleading claims in marketing their Voltaren Osteo […]

Subscribe for instant access to all Lawyerly content.

Already a subscriber?

Lost your password?

Contact us to enquire about group subscriptions.

Reckitt Benckiser appeals Nurofen loss
Competition & Consumer Protection 2018-03-05 11:44 am By Cat Fredenburgh

Reckitt Benckiser has filed an appeal against GlaxoSmithKline, after a judge found the consumer goods giant misled consumers with claims that Nurofen was a more […]

Subscribe for instant access to all Lawyerly content.

Already a subscriber?

Lost your password?

Contact us to enquire about group subscriptions.

AstraZeneca resolves Crestor patent spat with Generic Health
Intellectual Property 2018-03-01 7:23 pm By Christine Caulfield

Pharmaceutical companies AstraZeneca and Generic Health have laid down their swords in a long-running patent dispute over AstraZeneca’s cholesterol drug Crestor, two-and-a-half years after the […]

Subscribe for instant access to all Lawyerly content.

Already a subscriber?

Lost your password?

Contact us to enquire about group subscriptions.

Reckitt Benckiser to feel pain of GSK’s costs in Nurofen case
Competition & Consumer Protection 2018-02-28 3:47 pm By Christine Caulfield

Reckitt Benckiser has been ordered to pay all of GlaxoSmithKline’s legal bill after a judge found the drug giant misled consumers with claims that Nurofen […]

Subscribe for instant access to all Lawyerly content.

Already a subscriber?

Lost your password?

Contact us to enquire about group subscriptions.

IP Australia shoots down Bayer patent
Intellectual Property 2018-02-23 8:17 pm By Christine Caulfield

IP Australia handed a win Thursday to a company challenging a Bayer animal drug patent, but gave Bayer two months to address the patent application’s […]

Subscribe for instant access to all Lawyerly content.

Already a subscriber?

Lost your password?

Contact us to enquire about group subscriptions.